Phase Holographic Imaging PHI AB (FRA:L5W) Research & Development: €0.89 Mil (TTM As of Oct. 2025)


What is Phase Holographic Imaging PHI AB Research & Development?

Phase Holographic Imaging PHI AB FRA:L5W Research & Development is €0.89 Mil as of Oct. 2025. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Phase Holographic Imaging PHI AB's Research & Development for the three months ended in Oct. 2025 was €0.25 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Oct. 2025 was €0.89 Mil.

Phase Holographic Imaging PHI AB  (FRA:L5W) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Phase Holographic Imaging PHI AB Research & Development Related Terms

Phase Holographic Imaging PHI AB Research & Development Historical Data

* Premium members only.

The historical data trend for Phase Holographic Imaging PHI AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phase Holographic Imaging PHI AB Research & Development Chart

Phase Holographic Imaging PHI AB Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 0.85 0.60 0.65 0.66

Phase Holographic Imaging PHI AB Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.11 0.27 0.26 0.25

Phase Holographic Imaging PHI AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.89 Mil mean?
Phase Holographic Imaging PHI AB (FRA:L5W) has a Research & Development of €0.89 Mil as of Oct. 2025. Research and development expense is the total cost for research and development activities. View historical data on Phase Holographic Imaging PHI AB and its competitors.
Is Phase Holographic Imaging PHI AB's Research & Development too high?
Phase Holographic Imaging PHI AB's current Research & Development is €0.89 Mil.
How does Phase Holographic Imaging PHI AB's Research & Development compare to ABT and BSX?
Phase Holographic Imaging PHI AB's Research & Development of €0.89 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Phase Holographic Imaging PHI AB and its competitors. Phase Holographic Imaging PHI AB's current Research & Development is €0.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phase Holographic Imaging PHI AB stock overvalued right now?
Phase Holographic Imaging PHI AB (FRA:L5W) has a current Research & Development of €0.89 Mil. The stock's GF Value™ is €0.23, compared to a current price of €0.04 — trading 81% below its estimated fair value. The current Research & Development is €0.89 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Phase Holographic Imaging PHI AB (FRA:L5W), the current Research & Development is €0.89 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phase Holographic Imaging PHI AB Business Description

Address Skiffervagen 48, Lund, SWE, 224 78
Phase Holographic Imaging PHI AB is a medical device company that develops and markets non-invasive time-lapse imaging instruments used for the quantitative long-term analysis of living cell cultures. The company's commercial HoloMonitor products are based on Quantitative Phase Imaging (QPI) technology, which is used for real-time cell quality evaluation. Geographically, it has presence in Lund, Sweden, with offices in Boston, MA and Winston-Salem, NC.